Highlights

• Avingtrans' medical imaging Business Adaptix signed a memorandum of understanding with bone-health software developer IBEX.

• The MOU targets integrating IBEX's CorteX bone-health software into Adaptix's Ortho350 portable 3D X-ray imaging platform.

• The partners aim to offer patients a pay-per-scan, point-of-care bone density report using DXA-equivalent biomarkers.

• Ortho350 already holds FDA 510(k) clearance and CE marking, while CorteX's FDA 510(k) submission remains pending.

One half of this Partnership is already cleared for the US market; the other is still awaiting its turn. Adaptix, the medical imaging unit of Avingtrans (LSE:AVG), has signed a memorandum of understanding with IBEX, setting out a shared aim to combine an approved portable 3D X-ray system with bone-health software that is still moving through the US regulatory process.

An MOU, not a contract

The agreement is a memorandum of understanding. It records the intention of the two companies to work together but is not a binding contract. Financial terms were not disclosed.

That status matters for how the announcement should be read. It sets a direction for cooperation between Adaptix, a unit of Avingtrans (LSE:AVG), and IBEX, with any commercial arrangement still to be agreed.

Bringing CorteX to Ortho350

The aim is to integrate IBEX's CorteX bone-health software into Ortho350, Adaptix's portable 3D X-ray platform.

Ortho350 has FDA 510(k) clearance and carries a CE mark. CorteX is at an earlier regulatory point: its FDA 510(k) submission is pending, which means the software is not yet commercially available in the United States.

A pay-per-scan model at the point of care

The partners are targeting a specific product: a bone density report delivered at the point of care, charged on a pay-per-scan basis. The report is intended to provide biomarkers equivalent to those from DXA.

Pairing a portable imaging system with analysis software is designed to let that report be produced where the patient is being seen. The pay-per-scan structure ties charges to each scan performed.

The announcement also refers to preliminary surveys indicating that patients would be willing to pay for such a report. No further detail on those surveys, such as sample size or pricing, is given.

Where Adaptix sits within Avingtrans

Adaptix is the medical imaging business of Avingtrans (LSE:AVG), and the Ortho350 platform is its portable 3D X-ray product. The IBEX memorandum adds a potential bone-health application to that platform, which already holds FDA 510(k) clearance and CE marking.

What an MOU Means in Practice

A memorandum of understanding records the shared intention of two parties to explore cooperation, but it does not oblige either side to complete a transaction. In this case, Adaptix and IBEX have agreed on a direction: integrating CorteX bone-health software into the Ortho350 platform. Any commercial arrangement, including pricing, rights and responsibilities, remains to be agreed, and financial terms were not disclosed.

Regulatory Position and Product Concept

The regulatory positions of the two products differ. Ortho350 holds FDA 510(k) clearance and a CE mark, which cover the United States and Europe respectively. CorteX has a 510(k) submission pending, so it is not yet commercially available in the United States. A 510(k) is a submission to the US Food and Drug Administration showing that a device is substantially equivalent to one already on the market. The partners are targeting a bone density report delivered at the point of care, charged on a pay-per-scan basis and intended to provide biomarkers equivalent to those from DXA, a widely used form of bone density measurement. Because Ortho350 is portable, the concept is to produce the report where the patient is seen rather than in a separate imaging department. The announcement also refers to preliminary surveys indicating that patients would be willing to pay for such a report, though it gives no further detail on sample size or pricing. The announcement therefore describes an early stage of cooperation, with the clearance process for CorteX the main regulatory step still to be completed. Readers following Avingtrans can look for later updates on the submission and on whether the MOU leads to a commercial agreement between the two companies.